According to the announcement from Weigao Blood Purification (603014.SH), the company plans to issue shares to acquire 100% equity of Shandong Weigao Purui Pharmaceutical Packaging Co., Ltd. (referred to as "Weigao Purui") held by Weigao Co., Weihai Shengxi, and Weihai Ruiming. The company's stock will resume trading on November 3, 2025 (Monday) at market opening.

Upon completion of this transaction, the company can expand its product line into the pharmaceutical packaging field by integrating the target company's technological accumulation and product layout. At the same time, after the completion of this transaction, by fully leveraging the listed company's advantages in hollow fiber filtration technology and the target company's rich customer resources in the biopharmaceutical field, both parties can achieve mutual empowerment in product technology reserves and sales channels for biopharmaceutical filter business, jointly exploring the upstream market of biopharmaceuticals with a focus on biopharmaceutical filters